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Abstract. 
 
Nuclear dots containing PML and Sp100 pro-
teins (NDs) play a role in the development of acute 
promyelocytic leukemia, are modified after infection 
with various viruses, and are autoimmunogenic in pa-
tients with primary biliary cirrhosis (PBC). PML and 
Sp100 gene expression is strongly enhanced by interfer-
ons (IFN). Based on immunostaining with a monoclonal 
antibody (mAb C8A2), a third protein, nuclear dot pro-
tein 52 (NDP52), was recently localized in NDs. Here 
we analyzed the cellular localization, expression, and 
structure of NDP52 in more detail. Our NDP52-specific 
sera revealed mainly cytoplasmic staining but no ND 
pattern, neither in untreated nor in IFN-treated cells. 
Cells transfected with NDP52 expression vectors 
showed exclusively cytoplasmic staining. In subcellular 
fractionation experiments, NDP52 was found in cyto-
plasmic and nuclear fractions. Unlike as described for 
Sp100 and PML, NDP52 mRNA and protein levels 
were only marginally enhanced by IFN 
 
g 
 
and not en-
hanced at all by IFN 
 
b
 
. NDP52 homodimerization but 
no heterodimerization with Sp100 or PML could be 
demonstrated. None of the 93 PBC sera tested con-
tained autoantibodies against NDP52. Finally, mAb 
C8A2 reacted not only with NDP52 but also with a 
conformation-dependent epitope on the Sp100 protein. 
These data imply that NDP52 forms homodimers but 
no heterodimers with Sp100 and PML, lacks autoanti-
genicity in PBC, localizes mainly in the cytoplasm, and 
is associated with the nucleus, but not with NDs. Fi-
nally, unlike Sp100 and PML, NDP52 expression is nei-
ther markedly enhanced nor localization detectably al-
tered by type I and II IFNs.
 
T
 
he
 
 nucleus of eukaryotic cells is a highly complex
structure that consists of different domains as de-
fined by structural and/or functional characteristics
(Strouboulis and Wolffe, 1996). Nuclear dots (NDs)
 
1
 
 are
structures of punctate shape within the cell nucleus and
belong to the heterogeneous group of nuclear bodies (Brasch
and Ochs, 1992). They were originally discovered as au-
toimmune targets in patients suffering from primary bil-
iary cirrhosis (PBC), a chronic progressive liver disease of
systemic autoimmune character (Bernstein et al., 1984;
Powell et al., 1984). Since NDs do not colocalize with other
known subnuclear structures such as spliceosomes, coiled
bodies, interchromatin granules, or DNA-replication sites,
they represent novel nuclear domains, recently also desig-
nated as nuclear domain 10 (ND10), PML-containing on-
cogenic domains (PODs), or Kr-Bodies (Ascoli and Maul,
1991; Dyck et al., 1994; Weis et al., 1994).
The first protein component of NDs characterized bio-
chemically as well as by cloning and sequencing of the
cDNA was the Sp100 protein (Szostecki et al., 1987, 1990),
an interferon (IFN)-inducible acidic protein with a highly
aberrant electrophoretic mobility and transcription trans-
activating properties (Xie et al., 1993; Guldner, H.H., C.
Szostecki, and H. Will, manuscript submitted for publica-
tion). Unlike the single copy human Sp100, the homolo-
gous gene in mice, mSp100, is highly amplified and in
some populations visible as an inherited homogeneously
staining region on chromosome 1 (Plass et al., 1995; Grötz-
inger et al., 1996
 
a
 
). As recently demonstrated, several al-
ternatively spliced mRNAs and proteins are expressed
from the human Sp100 gene (Szostecki, 1991; Xie et al.,
1993; Dent et al., 1996; Grötzinger et al., 1996
 
c
 
; Guldner,
H.H., C. Szostecki, and H. Will, manuscript submitted for
publication) similar for the PML gene (Fagioli et al., 1992;
Pandolfi et al., 1992).
NDs gained broader interest when the PML protein,
known to be expressed as a fusion protein with the retinoic
acid receptor 
 
a
 
 (RAR
 
a
 
) in patients with acute promyelo-
cytic leukemia (de Thé et al., 1990), was localized in NDs.
The PML/RAR
 
a
 
 fusion protein is a neooncogene aber-
rantly expressed as a result of the t(15;17) chromosomal
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translocation that is the hallmark of this disease (Rowley
et al., 1977). Expression of the PML/RAR
 
a
 
 protein dis-
rupts the normal ND pattern and leads to a microspeckled
and partially cytoplasmic distribution of the proteins (Ko-
ken et al., 1994; Weis et al., 1994). This is probably suffi-
cient for blocking of promyelocytic differentiation and
transformation of the cells (Altabef et al., 1996). PML is
induced by type I and II IFNs with similar kinetics as
Sp100 (Chelbi-Alix et al., 1995; Lavau et al., 1995; Grötz-
inger et al., 1996
 
c
 
), probably due to a similar but not iden-
tical promoter configuration (Grötzinger et al., 1996
 
b
 
;
Stadler et al., 1995). Finally, both PML and Sp100 are au-
toantigens in PBC (Szostecki et al., 1992; Sternsdorf et al.,
1995). Autoantibodies against both antigens frequently co-
occur in the same patients, suggesting a direct or indirect
association of the two proteins in the same complex
(Sternsdorf et al., 1995). Recently, a leukocyte-specific
ND-component with high sequence similarities to Sp100
was identified by two independent groups. This protein is
also autoantigenic in PBC and has been designated Sp140
(Bloch et al., 1996) or LYSP100 (Dent et al., 1996).
Other less well-studied proteins were localized in NDs
by immunostaining with monoclonal antibodies (Ascoli
and Maul, 1991; Kamei, 1995) or autoimmune sera (Zuber
et al., 1995). Besides Sp100, Sp140, and PML, three further
putative ND proteins, Int-6, PIC1, and nuclear dot protein
52 (NDP52), have recently been characterized genetically
and in part also functionally. Similarly to PML, the Int-6
protein is involved in tumorigenesis (Desbois et al., 1996).
The PIC1 protein was discovered because of its direct in-
teraction with PML (Boddy et al., 1996).
The NDP52 cDNA was isolated by immunoscreening of
an expression library (Korioth et al., 1995) with a mono-
clonal antibody (mAb C8A2) obtained by immunization
of mice with crude nuclei fractions (Martelli et al., 1992).
NDP52 is a protein with a predicted molecular mass of 52
kD. The carboxy terminus of the protein shows homology
with LIM domains, and the central portion exhibits an ex-
tended coiled-coil domain containing a leucine zipper mo-
tif (Korioth et al., 1995). Similarly to PML and Sp100
(Carvalho et al., 1995), NDP52 was reported to relocate
after infection with herpes simplex virus type 1 (HSV 1),
adenovirus (Korioth et al., 1995; Ishov and Maul, 1996),
and cytomegalovirus (Korioth et al., 1996). Similarly to
PML and Sp100, IFN 
 
g
 
 was reported to enhance the steady-
state levels of NDP52 mRNA as shown by Northern blot-
ting, and IFN type I and II treatment increased the size
and number of NDP52-specific dots when immunostained
with monoclonal antibody C8A2 (Korioth et al., 1995).
To confirm the NDP52 location in NDs and to learn more
about the architecture of NDs, we analyzed the NDP52
protein in more detail. We found that mAb C8A2 does not
only react with the NDP52 protein but also with Sp100.
Our polyclonal anti-NDP52 sera showed mainly cytoplas-
mic and diffuse nuclear staining but no ND staining. Further-
more, unlike the case for PML and Sp100, NDP52 mRNA
and protein steady-state levels were not found to increase
after treatment with IFN 
 
b
 
 and only weakly after IFN 
 
g
 
. Fi-
nally, strong homomeric NDP52 protein/protein interaction
was demonstrated. Taken together, these data indicate that
NDP52 is mainly a dimeric/multimeric cytoplasmic and nu-
cleus-associated protein but not an ND-associated protein.
 
Materials and Methods
 
Isolation of RNA and Northern Blotting
 
Total RNA was isolated according to the acidic phenol/guanidiniumthio-
cyanate method using standard protocols (Chomczynski and Sacchi,
1987). Northern blotting and hybridization of RNAs with 
 
32
 
P-labeled
probes were performed as described (Sambrook et al., 1989). Blots were
exposed to imaging screens (Fuji Photo Film Co., Tokyo, Japan) and the
signals were quantitated by a bio imaging analyzer (model Fujix BAS
2000; Fuji Photo Film Co.).
 
Reverse Transcription, PCR Amplification, Cloning, 
and DNA Sequencing
 
100 ng total RNA isolated from HeLa S3 cells were incubated with an an-
chored oligo (dT)-primer (5
 
9
 
-TTTTTTTTTTTAA-3
 
9
 
) for 10 min at 65
 
8
 
C
and reverse transcribed using SuperScript reverse transcriptase (Strat-
agene, La Jolla, CA). PCR was performed in several independent 50-
 
m
 
l
reaction mixtures containing 50 mM Tris-HCl, pH 9.1, 3.5 mM MgCl
 
2
 
, 16
mM (NH
 
4
 
)
 
2
 
SO
 
4
 
, 150 
 
m
 
g/ml BSA, 0.2 mM dNTPs, 20 pmol of each primer,
and a mixture of 2.5 U of Taq DNA polymerase (Boehringer Mannheim,
Penzberg, FRG) and 0.08 U Pfu DNA polymerase (Stratagene) (Barnes,
1994). As primers, oligonucleotides NDP-5
 
9
 
 (5
 
9
 
-GCCGCTGCTGGT-
TGCTGTCC-3
 
9
 
) and NDP-3
 
9
 
 (5
 
9
 
-TCAGGTTAGGCAGGATCTTGA-
CTC-3
 
9
 
) were used. DNA fragments were amplified for 40 cycles in a
Thermocycler (HyBaid Omnigene; MWG Biotech, Ebersberg, FRG). Re-
actions were performed with the profile 30 s 95
 
8
 
C, 1 min 56
 
8
 
C, and 3 min
72
 
8
 
C. PCR reaction products were pooled, gel purified, and cloned into
the AT-cloning vector pXcm-Kan12, which resulted in plasmid pX-NDP.
This vector is a pUC18-derivative containing the kanamycin (kan) resis-
tance gene flanked by two synthetic XcmI restriction enzyme cleavage
sites. Upon restriction cleavage of this plasmid with XcmI, the kan gene is
released and single-T overhangs are created at the ends of the linearized
vector. PCR fragments inserted into this vector were excised by BamHI
digestion.
Three independently cloned NDP52 cDNAs were sequenced using the
Taq-Cycle sequencing protocol with IRD-41–labeled primers (MWG Bio-
tech) and a Li-COR automated sequencing device.
For expression of NDP52 as a fusion protein, the NDP52 cDNA ob-
tained by BamHI digestion from plasmid pX-NDP was cloned in-frame
into the prokaryotic expression vector pEx42 a, b, or c (Stemler et al.,
1990) linearized by BamHI. The protein expressed contains at its NH
 
2
 
 ter-
minus phage MS2-polymerase sequences (14 kD) followed by the full-
length NDP52 sequence. Production of recombinant Sp100 protein frag-
ments (Sp-AB, -CD, -DF, -GH, and -FL) used for immunoblotting with
mAb C8A2 is described elsewhere (Szostecki et al., 1992). For in vitro
transcription and expression in eukaryotic cells, the same BamHI frag-
ment was inserted into the BamHI site of plasmid pSG5 (Green et al.,
1988), which resulted in plasmid pSG5-NDP.
 
Cells, Cytokines, Transfections, and Indirect 
Immunofluorescence Microscopy
 
Human HEp-2, HeLa S3, MG63, and Rat R1H cells (Zywietz et al., 1995)
were maintained in DME (GIBCO BRL, Gaithersburg, MD) supple-
mented with 10% FCS. Human IFN 
 
b
 
 and 
 
g
 
 were used at a concentration
of 1,000 U/ml and added to the medium for 16–20 h. Plasmid DNAs were
introduced into cells by the calcium phosphate procedure (Sambrook et
al., 1989). 1–5 
 
m
 
g of pSG5-NDP, pSG5-Sp100, or pSG5-PML plasmids ad-
justed to 10 
 
m
 
g DNA with pUC19 were precipitated per 6-cm dish. Cal-
cium phosphate–DNA coprecipitates were left on the cells overnight and
removed by changing the medium, and cells were then incubated for a fur-
ther 24 h. For indirect immunofluorescence staining, cells were grown on
coverslips and treated as indicated. Cells were fixed either in 1% freshly
prepared paraformaldehyde in PBS (8 mM Na
 
2
 
HPO
 
4
 
, 1.5 mM KHPO
 
4
 
,
140 mM NaCl, 2.6 mM KCl, pH 7.3) for 5 min, followed by permeabiliza-
tion in PBS containing 0.2% Triton X-100 and 20 mM glycine for 20 min
(at room temperature), or at 
 
2
 
20
 
8
 
C for 5 min in methanol and for 20 s in
acetone. Rabbit or rat anti-NDP52 antisera were diluted from 1:200–
1:1,600 in PBS as indicated. The rat anti-Sp100 (Sp26) and rat anti-PML
(anti–PML-N) antibodies were diluted 1:400. The dilutions of the mono-
clonal antibodies (in PBS) are indicated in the text. Cells were incubated
with antibodies for 30 min at room temperature. For detection, DTAF- or
LRSC-conjugated donkey anti–mouse, goat anti–rabbit, or donkey anti– 
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rat IgG antibodies (Dianova GmbH, Hamburg, FRG) were diluted 1:200
in PBS and incubated as above.
 
Mammalian Two-Hybrid Interaction Assay
 
For in vivo interaction studies, the CLONTECH MATCHMAKER mam-
malian two-hybrid assay system (CLONTECH Labs, Palo Alto, CA) and
HuH-7 hepatoma cells were used. Full-length NDP52, PML, and Sp100
cDNAs were each cloned in-frame into plasmids pM and pVP16 for ex-
pression of the corresponding fusion proteins with the Gal4 DNA binding
domain and the VP16 transactivation domain, respectively. Full-length
PML and NDP52 were cloned as EcoRI-BamHI fragments and Sp100
cDNA as EcoRI-SalI fragment. Reporter gene assays were performed us-
ing plasmid pG5CAT according to the manufacturer’s protocol (CLON-
TECH Labs). Cells on a 60-mm Petri dish were transfected with 0.2 pmol
pM and pVP16 constructs, 0.7 pmol of the reporter construct, and 1 
 
m
 
g of
pCMV-
 
b
 
Gal to standardize transfection efficiencies. CAT activity was de-
termined with a commercial CAT-ELISA (Boehringer Mannheim).
 
Cell Extracts, Immunoblotting, and Antibodies
 
Preparation of total cellular protein extracts, SDS-PAGE (10 or 12.5%
polyacrylamide) of proteins, and transfer onto nitrocellulose filters were
carried out according to standard protocols (Sambrook et al., 1989). Blots
were blocked in 5% (wt/vol) dry milk in water and incubated with primary
antibodies in the same buffer. After washing four times in TBS (10 mM
Tris-HCl, pH 7.6, 150 mM NaCl) or PBS, blots were incubated with horse-
radish peroxidase–conjugated secondary antibody (Dianova GmbH) as
described above. For visualization of proteins, enhanced chemilumines-
cence was used (Amersham, Buckinghamshire, UK). Anti-NDP antibod-
ies and human autoimmune sera were diluted 1:1,000 and 1:2,000, respec-
tively. The mAb C8A2 was diluted 1:5 in 5% dry milk (in water) or 0.5%
dry milk (in PBS). Secondary antibodies were diluted 1:10,000. Antibodies
against gel-purified MS2–NDP52 fusion protein were produced by immu-
nization of rats and rabbits with the antigen emulsified in Freund’s adju-
vants. Sera from patients with clinically and histologically proven PBC
were provided by Dr. E.J. Heathcote (The Toronto Hospital, Toronto,
Ontario, Canada); Drs. M.C. Jung, U. Spengler, and G.R. Pape (Institut
für Immunologie, Universität München, FRG); R. Klein and P.A. Berg
(Medizinische Klinik und Poliklinik, Universität Tübingen, FRG); H.-J.
Lakomek (Klinik für Rheumatologie und physikalische Medizin, Minden,
FRG); and M. Manns (Medizinische Hochschule, Hannover, FRG).
 
ELISA
 
Enzyme-linked immunosorbent assay (ELISA) was essentially carried out
as described previously (Szostecki et al., 1992). Briefly, ELISA plates
were coated with recombinant gel-purified NDP52 protein in 8 M urea for
2 h at room temperature. After washing the plates were blocked overnight
at 4
 
8
 
C, washed, and incubated with a 1:100 dilution of PBC sera in PBS.
Bound autoantibodies were detected with peroxidase-coupled antibodies
against human IgG and orthophenylenediamine as substrate. OD
 
492
 
 val-
ues of 0.3 or below after 20 min of incubation obtained with control sera
from healthy persons were defined as negative. In this test, an anti-Sp100
positive control PBC-serum resulted in an OD
 
492
 
 of 2.5.
 
Subcellular Fractionation
 
Cells grown as monolayer were harvested, washed once with PBS, and re-
suspended in hypotonic buffer A (10 mM Hepes, 1.5 mM MgCl
 
2
 
, 10 mM
KCl, 0.5 mM PMSF) (Dignam et al., 1983). After 15 min of swelling on ice,
cells were homogenized carefully by 20–25 strokes in a Kontes all-glass
Dounce homogenizer (Type B pestil). After centrifugation at 800 
 
g
 
 for 10
min (4
 
8
 
C), the resulting supernatant was transferred into a new tube,
cleared by a second centrifugation step at 10,000 
 
g
 
, and precipitated by ad-
dition of 10 vol ice-cold acetone. After drying, the precipitate was boiled
for 10 min in 4 vol 2
 
3
 
 SDS-loading buffer of the initial cell pellet. The pel-
let containing crude nuclei was washed in a large volume of buffer A and
resuspended in 2 vol buffer A
 
9
 
 (buffer A supplemented with 0.5 mM DTT
and 1% NP-40) of the initial cell pellet. After incubation on ice for 10 min,
the supernatant was removed, cleared as described above, mixed with an
equal volume of 2
 
3
 
 SDS-loading buffer (Sambrook et al., 1989), and
boiled for 10 min. The remaining nuclei were again washed in buffer A
 
9
 
,
pelleted at 10,000 
 
g
 
, resuspended in 4 vol 2
 
3
 
 SDS-loading buffer of the
initial cell pellet, sonicated three times for 20 s, and boiled for 10 min. Cell
extracts were stored at 
 
2
 
20
 
8
 
C.
 
Synthesis of Radiolabeled PML, Sp100, NDP52, and 
Luciferase Proteins and Immunoprecipitation
 
In vitro transcription/translation and immunoprecipitation was carried out
as described previously (Sternsdorf et al., 1995). The plasmids pSG5-PML
(de Thé et al., 1991), pSp64-Sp100 (Sp100 cDNA inserted as HindIII-
EcoRI fragment into plasmid pSp64), and pSG5-NDP were linearized by
digestion with appropriate restriction enzymes. From these plasmids, run-
off RNAs encoding full-length PML, Sp100, and NDP52 proteins, respec-
tively, were produced using standard protocols for T7 (pSG5-PML, pSG5-
NDP) and Sp6 (pSp64-Sp100) RNA polymerase. In vitro translation was
carried out in rabbit reticulocyte lysate (Promega Corp., Madison, WI)
with or without the presence of [
 
35
 
S]methionine according to the manufac-
turer’s protocol. In addition, [
 
35
 
S]methionine-labeled luciferase translated
in this system from the corresponding mRNA (Promega Corp.) was used
as a control. An aliquot of each translation mixture was analyzed by SDS-
PAGE to determine the amounts of radiolabeled protein. For interaction
studies, the immunoprecipitates were washed in PBS. For immunoprecipi-
tation with autoimmune sera, NET
 
Gel
 
 Buffer (Sambrook et al., 1989) was
used. Gels were washed in 5% sodium acetate, dried, and exposed to x-ray
films or imaging screens (Fuji Photo Film Co.).
 
Results
 
Cloning and Sequencing of the NDP52 cDNA
 
A full-length NDP52 cDNA was obtained by reverse tran-
scriptase PCR using RNA from HeLa S3 cells. To exclude
artificial mutations introduced during amplification, three
independent reactions were performed. The resulting 1.4-
kb NDP52 cDNA fragments were pooled and cloned, and
finally three independent cDNA inserts were sequenced.
One of the three clones was identical in sequence to that
isolated previously from osteosarcoma cell line MG63
(Korioth et al., 1995), except for a single C to G nucleotide
change at position 1219. The point mutation predicts an
amino acid substitution of proline by alanine at amino acid
position 389. Since this substitution was present in all three
clones, it corresponds most likely to an allelic sequence
variation of the NDP52 gene of HeLa S3 cells. This clone
was used for further analysis, including the expression of
recombinant NDP52 protein for the generation of poly-
clonal antisera in rabbit and rat. The other two clones con-
tained one and four additional point mutations, respec-
tively, presumably introduced during PCR reaction. The
allelic exchange is located downstream of the predicted
coiled-coil region (amino acids 134–350) and upstream of
the LIM-homologous region (amino acids 395–446). There-
fore, it is unlikely to affect these two putative functional
domains. Furthermore, no obvious potential nuclear local-
ization signal is present in the vicinity of the amino acid
substitution. Taken together, it is unlikely that the NDP52
proteins expressed from the allelic genes in HeLa S3 and
MG63 cells behave differently.
 
IFN Inducibility of NDP52
 
In the previous report (Korioth et al., 1995), enhanced
NDP52 gene expression after IFN treatment of cells was
demonstrated by immunofluorescence staining and North-
ern blotting. To demonstrate IFN-enhanced NDP52 pro-
tein expression also by immunoblotting and to test the
specificity of the raised antisera, we used total cell extracts 
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of untreated and IFN-stimulated cells and, as a control, in
vitro–translated NDP52. Both sera generated by us recog-
nized a protein of 
 
z
 
55–58 kD in extracts of HEp-2, HeLa
S3, and MG63 cells that comigrated with the in vitro–
translated NDP52 protein (shown for the rabbit antiserum
in Fig. 1, 
 
left
 
; NDP52 indicated by 
 
arrow
 
). This experiment
shows that detection of NDP52 by immunoblotting can be
achieved with total cell lysates. Taken together, our data
demonstrate the specificity of the sera that allow highly
sensitive detection of NDP52 and suggest that the NDP52
protein is not subject to major posttranslational modifica-
tions. Unexpectedly, these antibodies revealed no increase
of NDP52 in three different IFN 
 
b
 
–treated cell lines com-
pared to nontreated cells and showed only a very minor in-
crease in IFN 
 
g
 
–treated cells (Fig. 1, 
 
left
 
, lanes 
 
b
 
 and 
 
g
 
). In
contrast, immunoblots performed with the same extracts,
and an Sp100-specific antibody showed the expected
strong inducibility of Sp100 by IFN 
 
b
 
 and less strong in-
ducibility by IFN 
 
g
 
 in HEp-2 and HeLa S3 cells (Fig. 1,
 
right
 
; Sp100-specific bands indicated by 
 
arrows
 
). In MG63
cells, IFN-increased Sp100 expression was hardly detect-
able, presumably because of a constitutive high level be-
fore treatment (Fig. 1, 
 
right
 
). To test whether only the
NDP52 mRNA (Korioth et al., 1995) but not the NDP52
protein levels are enhanced by IFN, we measured the
NDP52 and, as a control, the Sp100 mRNA levels in IFN-
treated and untreated HEp-2 cells. HEp-2 cells were cho-
sen for this experiment since they were found to be highly
responsive to IFN treatment on the protein level (see
above). Northern blotting did not reveal an increase of
NDP52 mRNA levels by IFN 
 
b
 
 (Fig. 2, 
 
NDP52
 
) and re-
vealed only a slight increase by IFN 
 
g
 
 (twofold, as deter-
mined by quantitation of the image normalized by 
 
b
 
-actin),
whereas the Sp100 mRNA levels increased as expected (Fig.
2, 
 
Sp100
 
). Taken together, these data demonstrate that
IFN 
 
g
 
 increases NDP52 gene expression only slightly and
IFN 
 
b
 
 does not increase expression at all in any of the
three cell lines tested.
 
Intracellular Localization of NDP52 Protein as Studied 
by Indirect Immunofluorescence Staining
 
As a prerequisite for studies on the interaction of NDP52
with other ND proteins, we analyzed the suitability of the
polyclonal anti-NDP52 antisera for detection of NDP52
protein expressed from the endogenous genes or from
transfected plasmids in HeLa S3 and HEp-2 cells by im-
munofluorescence staining. In addition, the MG63 os-
teosarcoma cell line used for the initial localization studies
(Korioth et al., 1995) was also tested here because it was
reported to express high levels of endogenous NDP52.
Untransfected MG63 cells treated with IFN 
 
g
 
 for maximal
expression of NDP52 showed weak staining only, which
required long exposure times for photographic documen-
tation (Fig. 3). Both sera used resulted in a coarse-grained
cytoplasmic staining often concentrated adjacent to the
nucleus and in addition, depending on cell type and fixa-
tion conditions, a diffuse nuclear staining (Fig. 3 
 
B
 
, rat
anti-NDP52 and Fig. 3 
 
C
 
, rabbit anti-NDP52). No ND
staining could be observed, irrespective of the fixation
conditions and the cell type used. The diffuse nuclear
staining was most prominent in HEp-2 cells after
paraformaldehyde fixation (Fig. 3 
 
B
 
) and hardly visible in
HeLa S3 cells after methanol-acetone fixation (Fig. 3 
 
C
 
,
nontransfected cells). Control staining with preimmune
sera also showed some nonspecific nuclear staining in
paraformaldehyde-fixed cells when exposed for the same
time. This indicates that the nuclear staining observed is in
part or totally caused by binding of unspecific antibodies
already present in the preimmune sera (Fig. 3 
 
A
 
). Both the
intensity and the staining patterns were not influenced by
IFN 
 
b
 
 or 
 
g
 
 treatment in HeLa S3, HEp-2, and MG63 cells
(data not shown). In no case could ND staining be de-
tected with any of our NDP52-specific polyclonal antisera.
Note that the same cells of Fig. 3 
 
B
 
 stained in addition with
a polyclonal rat anti-Sp100 serum showed the typical ND
pattern in the nucleus (Fig. 3 
 
B
 
9
 
).
Figure 1. Immunoblot analy-
sis of in vitro–translated pro-
tein and total cell extracts of
HEp-2, HeLa S3, and MG63
cells, separated by 12.5%
SDS-PAGE. In vitro–trans-
lated NDP52 detected by
the polyclonal rabbit anti-
NDP52 antiserum exhibits an
electrophoretic mobility cor-
responding to a protein of
56–58 kD (lane 2). No spe-
cific reaction is seen using
reticulocyte lysate alone
(lane  1). In HEp-2, HeLa S3,
and MG63 cells, endogenous
NDP52 has the same electro-
phoretic mobility (lanes 3–11,
marked by an arrow). Treat-
ment of cells with IFN b (lanes 4, 7, and 10) and g (lanes 5, 8, and 11) does not increase the amount of NDP52 (IFN b), or only increases
it marginally (IFN g). Immunoblot analysis of the same extracts using a polyclonal rat anti-Sp100 antiserum (lanes 12–20) in the HEp-2
and HeLa S3 cell lines shows a strong induction of Sp100 proteins (specific complexes indicated by arrows) by IFN b (lanes 13 and 16)
and a weaker induction by IFN g (lanes 14 and 17). MG63 cells, in contrast, showed only weak inducibility by both IFN b (lane 19) and
IFN g (lane 20).Sternsdorf et al. Nuclear Dot Protein 52 and Nuclear Domains 439
These data raised the question as to whether our sera
recognize NDP52 in immunofluorescence analysis at all.
We first compared the staining of HEp-2 cells by mAb
C8A2 and our polyclonal rabbit anti-NDP52 serum. With
both antibodies, coarse-grained cytoplasmic and diffuse
nuclear staining was observed (Fig. 3, E and D), but mAb
C8A2 in addition stained NDs. This finding implies that
our serum either does not recognize NDP52 or that mAb
C8A2 also cross-reacts with an ND-associated protein. To
examine this directly, we first transiently transfected HeLa
S3 and HEp-2 cells with the pSG5 expression vector con-
taining the NDP52 cDNA under the control of the SV-40
promoter (pSG5-NDP) and analyzed the cells by indirect
immunofluorescence. In the vast majority of these cells,
overexpressed NDP52 was localized in the cytoplasm, and
in very few cells, it was also found diffusely in the nucleus
(Figs. 3 C and 4, A and D). In contrast, Sp100 or PML pro-
teins transiently overexpressed in cells transfected with
the corresponding plasmids localized, as expected, pre-
dominantly in the nucleus (Fig. 4, B and C, respectively).
Serial dilutions of our NDP52 antisera unequivocally de-
tected transiently overexpressed NDP52 protein in trans-
fected cells up to the highest dilution tested (1:1,600; data
not shown). These results show that the polyclonal sera re-
act with NDP52 in eukaryotic cells even at high serum di-
lutions and strongly indicate that the staining pattern seen
in nontransfected cells reflects the distribution of the en-
dogenous NDP52 protein.
To address the question of whether the cytoplasmic lo-
calization of NDP52, when expressed from a recombinant
plasmid, might be due to an overload of the nuclear import
mechanism of the cell, we cotransfected HEp-2 cells with
NDP52 and PML expression vectors (Fig. 4). Cells ex-
pressing moderate levels of NDP52 showed mostly coarse-
grained cytoplasmic staining (Fig. 4 D, left cell), whereas
cells expressing high levels of the protein also exhibited
diffuse nuclear staining (Fig. 4 D, right cell). At this expo-
sure time, endogenous NDP52 is not visible. As expected,
the same cells stained with a PML-specific antibody
showed PML localization exclusively in nuclear dots in
transfected and nontransfected cells (Fig. 4 E). Fig. 4 F
shows both anti-NDP52 and anti-PML staining patterns
superimposed. Cotransfection experiments using NDP52
and Sp100 expression vectors yielded similar results (data
not shown). These data indicate that cytoplasmic localiza-
tion of NDP52 expressed in transfected cells is not due to
impaired nuclear import.
Subcellular Localization of NDP52 by
Biochemical Fractionation
Because of the intriguing discrepancies between the intra-
cellular localization of the NDP52 protein and the ND
proteins PML as well as Sp100 in transfected cells and be-
cause of the lack of ND-specific staining with the poly-
clonal antisera also in nontransfected cells, we determined
the intracellular localization of endogenous NDP52 by nu-
cleo-cytoplasmic fractionation and immunoblotting. Since
ND-specific staining after IFN treatment, as described for
HeLa cells, could be a result not only of increased
amounts of the protein but also of a different distribution
within the cell as speculated previously (Korioth et al.,
1995), both untreated and IFN-treated HEp-2 as well as
HeLa S3 cells were biochemically subfractionated. Endog-
enous NDP52 was detected in the soluble cytoplasmic, the
nuclear, and, to a minor extent, the detergent-extracted
cytoskeleton-associated fraction (Fig. 5 A, lanes C, N, and
E, respectively). No major NDP52 protein redistribution
was observed after treatment with IFN b or g (data not
shown). The purity of subcellular fractions was checked by
control incubations with human autoimmune sera recog-
nizing either the snRNP protein p68 localizing in the
nucleus (Theissen et al., 1986; Netter et al., 1990; Lamond
and Carmo-Fonseca, 1993) or the dihydrolipoamide acetyl-
transferase (74 kD, p74), which is a mitochondrial protein
(Van de Water et al., 1988). As expected, p68 was found
exclusively in the nuclear fraction (Fig. 5 B, arrow), and
p74 localized in the cytoskeleton-associated fraction (Fig.
5 C, arrow). These data indicate that NDP52 is localized in
the cytoplasm but is also associated with the nucleus. Our
data further indicate that no significant redistribution of
NDP52 takes place between the cellular compartments af-
ter IFN treatment. In addition, preliminary nucleoplasma/
nuclear matrix fractionation experiments using an estab-
lished procedure (Fey et al., 1986) also showed no redistri-
bution after IFN treatment (tested for IFN b, data not
shown).
Figure 2. IFN inducibility of NDP52 and Sp100 mRNAs as deter-
mined by Northern blot analysis. Total RNA of untreated (lanes
labeled [), IFN b– (lanes labeled b), and IFN g– (lanes labeled
g) treated HEp-2 cells was analyzed using radiolabeled full-
length NDP52 (lanes labeled NDP52), Sp100 (lanes labeled
Sp100), and b-actin (lanes labeled Beta-Actin) cDNAs as probes.
The amount of Sp100 mRNA is increased by IFNs b and g (fifth
and sixth lanes, respectively). The NDP52 mRNA level is not sig-
nificantly increased by IFN b and only weakly by IFN g (eighth
and ninth lanes, respectively).The Journal of Cell Biology, Volume 138, 1997 440
Figure 3. Immunofluorescence
staining of IFN g–treated MG63
cells fixed with paraformalde-
hyde (A and B), methanol/ace-
tone-fixed HeLa S3 cells (C) tran-
siently transfected with plasmid
pSG5-NDP, and HEp-2 cells fixed
with paraformaldehyde. Cells were
incubated with rat preimmune se-
rum (diluted 1:200) (A), polyclonal
rat anti-NDP52 (diluted 1:200) (B
and D), rabbit anti-NDP52 (diluted
1:800) (C), rabbit anti-Sp100 (di-
luted 1:400) (B9), and mAb C8A2
(diluted 1:3) (E). The anti-NDP52
polyclonal antiserum fails to de-
tect NDs but shows diffuse nu-
clear and granular cytoplasmic
staining (B and D), whereas the
anti-Sp100 antiserum shows the
typical ND staining in the same
cells (B9). The corresponding rat-
preimmune serum shows nonspe-
cific diffuse nuclear staining (A)
when photographic exposure was
identical to B. Hardly any nuclear
staining is detected in methanol/
acetone-fixed HeLa S3 cells (C).
NDP52 overexpressed in trans-
fected cells localizes predomi-
nantly in the cytoplasm (C). HEp-2
cells labeled with mAb C8A2
show the typical ND staining with
additional diffuse nuclear and
weaker coarse-grained cytoplas-
mic labeling (E, long exposure).
Except for the lack of ND stain-
ing, a very similar pattern is ob-
served when HEp-2 cells are
labeled with the polyclonal rat
anti-NDP52 antiserum (D). In
A–C, phase contrast pictures are
adjacent to the corresponding im-
munofluorescence staining photo-
graphs.  Bars, 10 mm.Sternsdorf et al. Nuclear Dot Protein 52 and Nuclear Domains 441
NDP52 Interaction Studies Using Immunoprecipitation
We next examined whether our failure to detect NDP52 in
NDs is due to the fact that only a very limited number of
epitopes is accessible to antibodies in immunofluorescence
analysis because of direct binding of NDP52 to PML and/
or Sp100, which would make NDP52 detection with our
polyclonal sera difficult. Sp100, PML, and NDP52 were
cotranslated with [35S]methionine in vitro in various com-
binations to allow complex formation in statu nascendi.
Proteins translated individually or together in one transla-
tion reaction were separated by SDS-PAGE (Fig. 6 A).
When Sp100 was cotranslated with PML or NDP52, the
amount of the latter two proteins was reduced, presum-
ably because of the particularly strong translation initia-
tion sequence context of the synthetic Sp100 mRNA used.
As a specificity control in the immunoprecipitation experi-
ments, in vitro–translated luciferase was added to the reac-
tion after cotranslation. Immunoprecipitation was performed
with rabbit anti-PML (Fig. 6 B) or rabbit anti-Sp100 (not
shown) antibodies, and the precipitates were analyzed by
SDS-PAGE and autoradiography. If a complex forms, one
or both of the other ND proteins should coprecipitate. Us-
ing anti-PML antibodies, the PML protein was precipi-
tated, but no coprecipitation of Sp100 or NDP52 occurred
(Fig. 6 B). This argues against a direct interaction between
any of the three in vitro–translated proteins.
NDP52 Interaction Studies Using the Two-Hybrid 
System in Eukaryotic Cells
To test potential interactions between NDP52 and PML
and/or Sp100 in vivo, we used the two-hybrid assay in
mammalian cells. All three proteins were expressed as fu-
sion proteins with either the yeast Gal4 DNA binding do-
main (plasmids pM-PML, pM-Sp100, and pM-NDP) or
the herpes simplex virus VP16 transactivating domain
(plasmids pV-PML, pV-Sp100, and pV-NDP) containing
an additional nuclear localization signal. As a reporter
gene, a plasmid containing a Gal4-responsive promoter
upstream of the CAT gene was used. Plasmids expressing
p53 and SV-40 large T (TAg) fusion proteins served as
positive controls (plasmids pM53 and pV-T). Results of
the transfection experiments are summarized in Table I.
Cotransfection of pM-NDP or pV-NDP with the corre-
sponding PML or Sp100 construct did not result in CAT
activity significantly above the negative controls (con-
structs with a viral core protein; data not shown). In con-
trast, cotransfection of pV-NDP/pM-NDP or pV-PML/
pM-PML showed a very strong and intermediate positive
signal, respectively. These data suggest that none of the
three proteins bind directly to each other and demonstrate
that both NDP52 and PML homodimerize. Homodimer-
ization of PML was shown previously by using different
techniques (Perez et al., 1993).
Figure 4. Immunofluorescence staining of paraformaldehyde-fixed HEp-2 cells transfected with NDP52 (A), Sp100 (B), and PML (C)
expression vectors and of methanol/acetone-fixed HEp-2 cells cotransfected with NDP52 and PML expression vectors (D–F). For de-
tection of expressed proteins, the following polyclonal sera (diluted 1:400) have been used: rat anti-NDP52 (A), rat anti-Sp100 (B), rat
anti-PML (C), and a mixture of rabbit anti-NDP52 and rat anti-PML (D–F). Sp100 and PML expressed in transfected cells show nuclear
localization (B and C, respectively) whereas NDP52 localizes in the cytoplasm (A). Cells cotransfected with NDP52- and PML-expres-
sion vectors also exhibit nuclear localization of PML (E, green label) and predominantly cytoplasmic localization of NDP52 (D, red la-
bel) within the same cell. The transfected cell on the right in D shows, in addition, some NDP52 diffusely distributed in the nucleus. F is
an overlay of the staining patterns shown in D and E.The Journal of Cell Biology, Volume 138, 1997 442
Screening of PBC Sera for Anti-NDP52 Autoantibodies
Two or several components are often coautoantigenic in
autoimmune diseases when they are part of the same mac-
romolecular complex (Tan, 1989, 1991). This is in fact also
the case for the PML and Sp100 proteins, as shown previ-
ously (Sternsdorf et al., 1995; Züchner et al., 1997). There-
fore, we tested whether PBC sera containing both PML
and Sp100 autoantibodies also have anti-NDP52 autoanti-
bodies. Radiolabeled NDP52 protein (Fig. 7, lane 1) mixed
with radiolabeled luciferase as a specificity control (Fig. 7,
lanes  2–6), were immunoprecipitated with each of five
anti-Sp100/PML positive PBC sera (PBC1-PBC5). In one
precipitation experiment, radiolabeled PML was added as
a control (Fig. 7, lane PBC3), which was, as expected, effi-
ciently precipitated by the anti-PML autoantibodies. In
contrast, none of the five sera precipitated NDP52 protein.
These data indicate that autoantibodies that recognize
NDP52 synthesized by in vitro translation are not present
in the PBC sera tested, whereas PML and Sp100 are recog-
nized very well (Sternsdorf et al., 1995).
To be able to screen a larger collection of PBC sera for
anti-NDP52 autoantibodies and also for antibodies that
recognize epitopes on denatured NDP52 proteins only, 48
PBC sera containing anti-Sp100 and/or anti-PML autoan-
tibodies were tested by ELISA using recombinant NDP52
protein produced in Escherichia coli as template (see Ma-
terials and Methods). Moreover, 45 additional anti-PML/
anti-Sp100 negative PBC sera showing a dotlike pattern in
immunofluorescence analysis were also screened. With the
exception of two sera, none showed NDP52 reactivity
above background (defined as ,0.3 OD by using non-PBC
sera as controls). The two sera with reactivity above back-
ground (OD 5 1.3 and 0.8, respectively) were shown by
immunoblotting to contain high levels of antibodies against
E. coli proteins and showed no specific anti-NDP52 reac-
tivity (data not shown). Taken together, these data strongly
suggest that NDP52 is not coautoimmunogenic with PML
and Sp100 in patients with primary biliary cirrhosis, which
provides further indirect evidence against an association
of NDP52 with a macromolecular ND protein complex.
mAb C8A2 Cross-reacts with the Sp100 Protein
To explain the discrepancy between the staining pattern of
our anti-NDP52 polyclonal serum and mAb C8A2, we ex-
amined whether the mAb C8A2 cross-reacts with PML or
Sp100. Therefore, we transfected HEp-2 and rat R1H cells
with NDP52, PML, or Sp100 expression vectors and com-
binations thereof and analyzed the cells by immunofluo-
rescence staining with the mAb C8A2 (Fig. 8, A–D). In
these experiments, we intentionally did not double-label
the cells with two different types of antibodies but rather
labeled only with mAb C8A2 since double-labeling can re-
sult in artifacts due to insufficient wavelength cutoffs of
the microscope filters or due to cross-species reactivity of
the secondary antibodies.
When the mAb C8A2 (20 mg/ml) was used for immu-
nostaining of HEp-2 cells, NDP52 synthesized from the
transfected vector was readily detected at a dilution of 1:200
and localized primarily in the cytoplasm (not shown). An
ND pattern was observed in neither transfected nor un-
transfected cells when using this dilution of antibody.
However, at higher mAb concentrations (dilutions 1:3 or
1:10) the typical ND staining pattern became apparent in
paraformaldehyde-fixed cells (Fig. 8 A). Methanol/ace-
tone-fixed cells did not show ND staining even when undi-
luted mAb C8A2 was used (not shown), suggesting a loss
of epitope recognition due to the fixation process. When
HEp-2 cells transfected with NDP52, with both NDP52
and Sp100, or both NDP52 and PML were immunostained
with a 1:3 dilution of mAb C8A2, the following patterns
were observed. NDP52 overexpressing cells showed bright
cytoplasmic staining with exclusion of the nucleus and, in
addition, a weak nuclear ND pattern both in the trans-
fected and the nontransfected cells (Fig. 8 A). In cells
overexpressing NDP52 and Sp100 simultaneously, en-
larged nuclear dotlike staining in addition to the cytoplas-
mic NDP52 staining was observed (Fig. 8 B). This strongly
suggests that mAb C8A2 not only recognizes NDP52 but
also recognizes Sp100. In contrast, in cells cotransfected
with NDP52 and PML expression vectors, no staining of
overexpressed PML protein by mAb C8A2 in any of the
NDP52 overexpressing cells (Fig. 8 C) was observed. Since
NDP52 and PML proteins were coexpressed in z90% of
the transfected cells (data not shown) when examining a
second coverslip from the same transfection immuno-
stained with polyclonal anti-NDP52 and anti-PML anti-
Figure 5. Nucleo-cytoplasmic fractionation of HEp-2 and HeLa
S3 cells. Cell fractions were separated by SDS-PAGE and ana-
lyzed by immunoblotting: Lanes labeled N, nuclear proteins;
lanes labeled E, nucleus/cytoskeleton-associated proteins (desig-
nated E for extraction); lanes labeled C, the soluble cytoplasmic
fraction. A shows detection of NDP52 (indicated by arrow) using
rabbit anti-NDP52 antiserum. NDP52 is detected in all three sub-
fractions. No redistribution is observed after treatment of the
cells with IFN b. As a control for purity of the subcellular frac-
tions, immunoblotting of the same extracts was performed using
human autoimmune sera recognizing the snRNP p68 protein,
which localizes in the nucleus (B, arrow) or the mitochondrial
p74 protein, which localizes in the cytoskeleton fraction (C, arrow). 
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bodies, we conclude that mAb C8A2 does not cross-react
with PML. In cells transfected only with the Sp100 expres-
sion vector and immunostained with various concentra-
tions of the mAb C8A2 (dilutions 1:3 and 1:50 are shown
in Fig. 8, 
 
D
 
 and 
 
E
 
), an enlarged, bright ND pattern typical
for overexpressed Sp100 protein was observed. Note that
the endogenous ND staining in the adjacent nontrans-
fected cells was strong using the 1:3 dilution (Fig. 8 
 
D
 
) but
drastically reduced in the 1:50 dilution (Fig. 8 
 
E
 
). Sp100
overexpressed from recombinant plasmids could be de-
tected easily with this antibody diluted down to 1:100 (not
shown). This shows that the mAb C8A2 recognizes over-
expressed Sp100 even at dilutions where it fails to stain en-
dogenous NDs. To exclude the possibility that the ND
structure itself is enlarged by the overexpression of the
Sp100 protein, which may mimic recognition of Sp100 by
the NDP52-specific mAb, and to further exclude the possi-
bility that the large amount of Sp100 expressed from the
expression vector might lead to artificial staining, we also
analyzed R1H rat cells. These cells showed neither endog-
enous ND staining with mAb C8A2 nor with any of our
Sp100- or PML-specific sera. These cells were transfected
with PML- (5 
 
m
 
g) and with different amounts of Sp100-
expression vector (5 and 1 
 
m
 
g) to be able to stain Sp100 ex-
pressed at physiological levels. In R1H cells transfected
with the PML expression vector, no staining of PML was
observed when using mAb C8A2 (data not shown),
whereas Sp100 was stained with the same antibody in
many cells, even when transiently expressed at low levels
(Fig. 8 
 
F
 
). However, the sensitivity of Sp100 detection by
mAb C8A2 is considerably lower than that achieved with
our polyclonal anti-Sp100 sera. In summary, these results
clearly demonstrate that mAb C8A2 recognizes in addi-
tion to NDP52 the Sp100 protein but not the PML protein,
implying that the ND staining with mAb C8A2 is due to
cross-reaction with the Sp100 protein. This was further in-
vestigated by performing immunoblotting experiments
with recombinant full-length Sp100 protein and a set of
overlapping subfragments thereof and as a positive control
with the recombinant NDP52 protein (see Materials and
Methods). No significant reactivity of the mAb C8A2 with
any of the Sp100 proteins was observed, whereas the re-
combinant NDP52 protein showed very strong reactivity
(data not shown). These data suggest that recognition of
Figure 6. In vitro–translated
NDP52 does not interact
with PML or Sp100. 35S-la-
beled proteins were gener-
ated by in vitro transcription/
translation.  A shows the
translation products ob-
tained with Sp100, PML,
NDP52, or luciferase RNAs
alone (lanes 1–4) and with
combinations of some of
these RNAs when translated
in the same tube (lanes 5–7).
All proteins were analyzed
by SDS-PAGE and subse-
quent autoradiography. Im-
munoprecipitation with rab-
bit anti-PML serum results in
precipitation of the PML
protein only (B, lanes 3, 5,
and  6). No coprecipitation of
NDP52 or Sp100 is observed
after cotranslation of the
proteins (lanes 5 and 6). Lu-
ciferase was added to all pre-
cipitation reactions as a neg-
ative control. Lanes 1 and 7
represent mixtures of the
translation reactions without
precipitation as indicated.
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pression. No NDP52 construct gives a signal above background when cotransfected
with the PML or the Sp100 constructs. The pV-NDP/pM-NDP combination and the
pV-PML/pM-PML combination, however, show a strong or intermediately strong
positive signal, respectively, indicating that NDP52, like PML, homodimerizes. 
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below detection limit.
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the cross-reactive epitope on Sp100 is conformation de-
pendent.
Discussion
In this study, we provided several independent lines of ev-
idence that NDP52 is not associated with NDs but was er-
roneously localized in previous studies because mAb
C8A2 cross-reacts with the Sp100 protein. NDP52 was lo-
calized here predominantly in the cytoplasm with a coarse-
grained distribution preferentially close to the nucleus.
Subcellular fractionation experiments are consistent with
the cytoplasmic localization and in addition showed that a
fraction of NDP52 is also associated with the nucleus.
NDP52 was shown to form homodimers but no het-
erodimers with Sp100 and PML. Unlike what is known for
Sp100 and PML, autoantibodies against NDP52 were not
found in ND-staining PBC sera. These findings and our
failure to demonstrate binding of NDP52 to Sp100 or PML
argue that NDP52 neither mediates interaction of ND pro-
teins nor is it part of the multiprotein ND complex. We
also found no increase in NDP52 mRNA and protein lev-
els after IFN b treatment and only little after IFN g treat-
ment of cells. Taken together, these data define (ND)P52
as a non–ND-associated dimeric or multimeric protein
with a mainly coarse-grained cytoplasmic localization.
The cross-reactivity of mAb C8A2 with Sp100 shown in
transfected cells by immunofluorescence staining offers a
simple and convincing explanation for the previously re-
ported erroneous localization of (ND)P52 to NDs (Kori-
oth et al., 1995), and for some but not all discrepant results
and observations. The increase in number and size of NDs
in MG63, HEp-2, and HeLa S3 cells after IFN b and g
treatment, as observed previously by immunostaining with
mAb C8A2 (Korioth et al., 1995) and confirmed in our
study, can be fully explained by the cross-reactivity with
the IFN-inducible Sp100 protein alone. Both the size and
number of dots were shown to increase in IFN b– and
g–treated cells when stained with anti-Sp100 antibodies
(Guldner et al., 1992). A significant increase in (ND)P52
protein expression in IFN g– and IFN b–treated MG63,
HEp-2, and HeLa S3 cells was seen by neither immunoflu-
orescence staining (data not shown) nor immunoblotting.
These findings are consistent with our failure to detect a
strong increase in NDP52 mRNA levels by Northern anal-
ysis in HEp-2 cells. The increase in NDP52 mRNA levels
reported for MG63 cells (Korioth et al., 1995) is not con-
sistent with our findings. The reason for this discrepancy
with previous data is not clear.
Because a weak nuclear staining was seen both with our
preimmune sera from the rabbit and the rat immunized
with recombinant (ND)P52 protein, we could not deter-
mine unequivocally whether (ND)P52 is an exclusively cy-
toplasmic protein or, in part, is also diffusely distributed in
the nucleus. The diffuse staining of nuclei of various cells
by mAb C8A2, which is found in addition to ND staining
(Korioth et al., 1995, and our data, Fig. 8), may be taken as
evidence against a purely cytoplasmic localization of (ND)P52.
However, the diffuse nuclear form of (ND)P52 in COS
cells, which was reported to reorganize into NDs after IFN
treatment (Korioth et al., 1995), can also be explained by
the cross-reactivity of mAb C8A2 with the Sp100 protein.
In COS cells, IFNs increase the amount of Sp100 (our un-
published data), which presumably makes Sp100 detect-
able by mAb C8A2. This assumption is compatible with
the observation that human HuH-7 hepatoma cells show
detectable ND staining with Sp100-specific sera only after
IFN treatment (unpublished data). Considering all the
above-mentioned points and our failure to demonstrate a
major intracellular redistribution of (ND)P52 in biochemi-
cal cell compartment fractionation experiments, we have
strong reasons to believe that the previously described
IFN-mediated change in cellular distribution of (ND)P52
actually represents IFN-enhanced Sp100 protein expres-
sion.
After infection with HSV-1 mutant FXE, and adenovi-
rus Ad5, the redistribution of the ND antigen recognized
by mAb C8A2 was reported to differ from that of Sp100
and PML (Korioth et al., 1995). Specifically, after infec-
tion with HSV-1 mutant FXE, C8A2 staining was shown
to disappear in early stages of infection, whereas Sp100
staining was still detectable (Korioth et al., 1995). This
finding could be taken as evidence against a possible cross-
reaction of mAb C8A2 with Sp100 and/or PML. However,
an alternative explanation for this finding could be that
the cross-reactive Sp100 epitope is either not accessible,
covered, or even destroyed after virus infection because of
a change in Sp100 protein conformation. Such a conforma-
tional change could well abolish Sp100 staining by mAb
C8A2 but not necessarily by polyclonal sera. Alternatively
or in addition, the lower sensitivity in staining of Sp100 by
mAb C8A2 compared to polyclonal anti-Sp100 (our data)
could play a role. The removal of mAb C8A2-reactive pro-
tein together with Sp100 from PML-containing tracks in-
duced by Ad5 virus and the colocalization of both antigens
in the infected cells (Korioth et al., 1995; Ishov and Maul,
1996) corroborate our assumptions.
Two sets of data indicate that mAb C8A2 recognizes, in
Figure 7. Failure of detection of NDP52 autoantibodies in sera
from PBC patients containing anti-PML and anti-Sp100 autoanti-
bodies by immunoprecipitation. Radiolabeled NDP52 and, as a
negative control, luciferase proteins were mixed and immunopre-
cipitated using five anti-Sp100/anti-PML double-positive PBC
sera (lanes PBC1–PBC5). In lane PBC3, radiolabeled PML was
included in the precipitation reaction as a positive control. The
first and last lanes represent mixtures of the translation reactions
as indicated.Sternsdorf et al. Nuclear Dot Protein 52 and Nuclear Domains 445
addition to NDP52, a conformation-dependent epitope on
the Sp100 protein. First, fixation of cells with methanol/
acetone completely abolished ND staining by mAb C8A2,
and Sp100 transiently expressed at high levels was recog-
nized less well (data not shown). Second, recombinant
subfragments of Sp100 expressed in E. coli showed no sig-
nificant reactivity in immunoblotting. Note that our study
does not exclude that the mAb C8A2 recognizes an Sp100-
Figure 8. Cross-reaction of mAb C8A2 with Sp100 but not PML in paraformaldehyde-fixed cells as revealed by immunofluorescence
staining. (A–C) Immunofluorescence analysis of HEp-2 cells transfected with NDP52 (A), Sp100 plus NDP52 (B), or PML plus NDP52
(C) expression vectors, respectively, using the mAb C8A2 at a dilution of 1:3. NDP52 localizes in the cytoplasm, and cells transfected
with Sp100 plus NDP52 also show an increased nuclear dotlike staining (B). Overexpressed PML is not recognized (C). D and E show
HEp-2 cells transfected with Sp100 expression vector alone (5 mg per 60-mm dish) and stained with the mAb C8A2 at dilutions of 1:3
and 1:50, respectively. Using a 1:50 dilution of mAb C8A2, overexpressed Sp100 is recognized, whereas the endogenous ND pattern is
hardly visible (E). F shows rat R1H cells transfected with the Sp100 expression vector (1 mg per 60-mm dish) and stained with mAb
C8A2 at a dilution of 1:3. For documentation, a cell with only weak expression was intentionally chosen. Sp100 is clearly recognized by
the mAb. No endogenous ND pattern is detectable as evident from the untransfected cell visible in the same picture. The corresponding
phase contrast pictures are given below the immunofluorescence pictures. Bar, 10 mm.The Journal of Cell Biology, Volume 138, 1997 446
specific epitope that is dependent on posttranslational
modification of Sp100, as this may not be present on Sp100
proteins expressed in bacteria and may be lost after the
fixation conditions used here. Infection with HSV or other
viruses might likewise lead to a specific loss of the modifi-
cation and therefore to loss of staining by mAb C8A2.
Taking these observations and considerations into ac-
count, loss of a single cross-reactive Sp100 epitope after
redistribution/displacement of proteins from NDs as medi-
ated by known viral proteins is very well conceivable.
Our conclusion that (ND)P52 is not a component of
NDs is supported by strong direct evidence, but also by in-
direct pieces of evidence. Unlike that described for Sp100
and PML, against which autoantibodies co-occur very fre-
quently (70%) in a subpopulation of PBC patients (Sterns-
dorf et al., 1995; Züchner et al., 1997), autoantibodies
against (ND)P52 protein were not detected in any of the 93
PBC sera tested. Together with the fact that autoantibod-
ies against several components of a macromolecular com-
plex are induced in many autoimmune diseases, including
PBC (Tan, 1989, 1991; Fatenejad et al., 1994), the absence
of (ND)P52 autoantibodies in ND-staining PBC sera pro-
vides additional, though indirect, evidence against the lo-
calization of the (ND)P52 protein in NDs. The lack of
(ND)P52 antibodies appears not to be due to low immu-
nogenicity of (ND)P52, as indicated by the high titered
(ND)P52 antibodies obtained by active immunization of
rabbits and rats with recombinant (ND)P52 protein used
by us. These data also argue against the presence of
(ND)P52 in NDs. This conclusion is also in line with our
failure to detect binding of (ND)P52 to PML or Sp100
protein by coprecipitation or by using the two-hybrid as-
say. However, the coprecipitation experiments provide no
strong argument, as we have shown here and previously
(Koken et al., 1994; Sternsdorf et al., 1995), that the PML
and Sp100 proteins, when synthesized in vitro, do not bind
directly to each other. Similar reasoning can be applied to
our failure to show heterodimerization between any of the
three proteins in the two-hybrid system. Note that a posi-
tive result in this system could theoretically also be ob-
tained when heterodimerization would be dependent on
additional cellular bridging proteins. Since a negative re-
sult in the two-hybrid system may always be caused by im-
proper folding of the fusion proteins, our data do not
firmly exclude heterodimerization of the three proteins
when expressed without a fusion partner in the cell. How-
ever, the homodimerization of PML, as seen in the two-
hybrid system and previously in coprecipitation experi-
ments (Perez et al., 1993) and which is known to be medi-
ated by the coiled-coil domain in the PML protein, argues
against a strongly aberrant conformation of PML when ex-
pressed as a Gal4- or VP16-fusion protein. The same is
probably true for the (ND)P52 protein, for which strong
homodimerization (stronger than SV-40 T-antigen/p53
heterodimerization) was evident in the two-hybrid system.
The putative central coiled-coil/leucine zipper and/or the
LIM domain predicted from the (ND)P52 protein se-
quence most likely trigger its dimerization. Taken to-
gether, the homodimerization of (ND)P52 and PML and
the lack of (ND)P52 heterodimerization with PML or Sp100
in this system strongly argue against a role for (ND)P52 in the
interaction between different ND proteins.
One of the controls for the localization of (ND)P52 to
NDs in the previous report was the staining of cells with a
polyclonal antibody against recombinant (ND)P52 protein
expressed in E. coli (Korioth et al., 1995). This polyclonal
antibody decorated ND-like structures similar to mAb
C8A2 (mentioned as data not shown in the paper). How-
ever, the authors have neither convincingly excluded
cross-reactivity of the anti-(ND)P52 polyclonal antibody
with Sp100 or PML nor have they demonstrated whether
the same NDs reacted with both types of antibodies. For
the following reasons we consider such controls as impor-
tant. First, a weak ND-like staining in few cells by some
polyclonal antibodies directed against proteins unrelated
to ND proteins, as occasionally observed in our laboratory
(unpublished data), suggests that ND proteins may be-
come autoantigenic upon vigorous unspecific stimulation
of the immune system. This may be due to the cell inflam-
mation induced by the adjuvants used for immunization.
Second, staining of cells with some polyclonal antibodies
directed against proteins unrelated to ND proteins occa-
sionally results in dot staining patterns that are different
from Sp100/PML-specific NDs. Third, the reaction of
mAb C8A2 both with (ND)P52 and Sp100 as well as the
fact that mAb C8A2 was produced by conventional immu-
nization with a nuclear protein fraction proves that there
are similar structures on both proteins against which cross-
reactive antibodies can be produced. Note, however, that
the lack of cross-reactivity of our anti-(ND)P52 and anti-
Sp100 polyclonal antisera with Sp100 and (ND)P52 pro-
teins, respectively, indicates that the cross-reactive epitopes
were not notably immunogenic in the animals we used.
mAbs recognizing different epitopes on more than one
protein or selectively only one epitope on a single protein
when one particular technique is used but two with an-
other technique are rather common (Dighiero et al., 1983).
Therefore, discrepancies between immunoblot and immu-
nofluorescence staining data encountered with mAbs are
not surprising. Interestingly, data published for two mAbs
directed against putative ND proteins indicate that they
react with more than one protein. First, mAb AP435 was
reported to stain not only NDs but also to react with
desmin, vimentin, and keratin 18 (Kamei, 1995). This mAb
reacted with neither the PML nor the Sp100 proteins used
in our studies (data not shown). Second, mAb 1150 (Ep-
stein, 1984), which also stains NDs (Ascoli and Maul, 1991),
reacts with the Sp100 protein (Doucas et al., 1996; our un-
published observations) when staining fixed cells in immu-
nofluorescence analysis, but it reacts with a 55-kD protein
(designated NDP55) on immunoblots (Ascoli and Maul,
1991). In summary, the data presented emphasize that ex-
treme care has to be taken for the localization of proteins
to specific cellular compartments and to NDs in particular.
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